Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 41 | 2025 | 268 | 8.160 |
Why?
| | Chemical and Drug Induced Liver Injury | 16 | 2023 | 138 | 4.600 |
Why?
| | Analgesics, Non-Narcotic | 22 | 2025 | 130 | 4.430 |
Why?
| | Drug Overdose | 32 | 2025 | 376 | 3.910 |
Why?
| | Poison Control Centers | 13 | 2025 | 85 | 3.340 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2357 | 2.990 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.810 |
Why?
| | Acetylcysteine | 12 | 2023 | 139 | 2.480 |
Why?
| | Alanine Transaminase | 14 | 2023 | 151 | 2.450 |
Why?
| | Cocaine | 10 | 2011 | 162 | 2.300 |
Why?
| | Cannabis | 9 | 2020 | 519 | 2.180 |
Why?
| | Prescription Drugs | 9 | 2018 | 110 | 2.090 |
Why?
| | Antidotes | 10 | 2023 | 145 | 1.590 |
Why?
| | Legislation, Drug | 5 | 2017 | 72 | 1.400 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1158 | 1.380 |
Why?
| | Cysteine | 4 | 2017 | 210 | 1.270 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 178 | 1.270 |
Why?
| | Marijuana Use | 4 | 2021 | 218 | 1.120 |
Why?
| | Medication Errors | 5 | 2015 | 86 | 1.100 |
Why?
| | Pain | 9 | 2020 | 787 | 1.020 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 132 | 1.010 |
Why?
| | Male | 103 | 2022 | 73014 | 1.010 |
Why?
| | Humans | 156 | 2025 | 145625 | 1.000 |
Why?
| | Emergency Medicine | 6 | 2019 | 278 | 1.000 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.000 |
Why?
| | Toxicology | 4 | 2021 | 49 | 0.990 |
Why?
| | Medication Reconciliation | 2 | 2016 | 31 | 0.900 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2018 | 0.890 |
Why?
| | Female | 96 | 2023 | 79080 | 0.880 |
Why?
| | Adult | 73 | 2022 | 40821 | 0.870 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.840 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.840 |
Why?
| | Antivenins | 5 | 2019 | 29 | 0.830 |
Why?
| | Diphenhydramine | 4 | 2023 | 36 | 0.820 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 5 | 0.810 |
Why?
| | Thiazoles | 4 | 2009 | 139 | 0.780 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 17 | 0.780 |
Why?
| | Spider Venoms | 4 | 2019 | 10 | 0.770 |
Why?
| | Benzodiazepines | 6 | 2023 | 156 | 0.770 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.740 |
Why?
| | Lorazepam | 3 | 2023 | 24 | 0.740 |
Why?
| | Heart Arrest | 8 | 2018 | 410 | 0.730 |
Why?
| | Young Adult | 30 | 2020 | 14240 | 0.710 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.690 |
Why?
| | Middle Aged | 54 | 2022 | 36359 | 0.690 |
Why?
| | Emergency Treatment | 4 | 2015 | 122 | 0.690 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 344 | 0.690 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.680 |
Why?
| | Piperazines | 4 | 2009 | 367 | 0.680 |
Why?
| | Medical History Taking | 3 | 2018 | 116 | 0.680 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 59 | 0.670 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 277 | 0.660 |
Why?
| | Seizures | 6 | 2011 | 489 | 0.660 |
Why?
| | Delirium | 2 | 2020 | 106 | 0.660 |
Why?
| | Referral and Consultation | 2 | 2020 | 878 | 0.660 |
Why?
| | Abdominal Pain | 2 | 2019 | 148 | 0.630 |
Why?
| | Suicide, Attempted | 5 | 2012 | 374 | 0.620 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 144 | 0.620 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 561 | 0.610 |
Why?
| | Back Pain | 1 | 2020 | 56 | 0.610 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 148 | 0.600 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 81 | 0.600 |
Why?
| | Buprenorphine | 2 | 2020 | 197 | 0.590 |
Why?
| | Haloperidol | 1 | 2019 | 27 | 0.580 |
Why?
| | Patient Handoff | 1 | 2020 | 45 | 0.580 |
Why?
| | Ketorolac | 1 | 2019 | 33 | 0.570 |
Why?
| | Retrospective Studies | 31 | 2023 | 17291 | 0.570 |
Why?
| | Emergency Medical Services | 5 | 2025 | 680 | 0.570 |
Why?
| | Social Work | 1 | 2020 | 84 | 0.570 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 24 | 0.560 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.550 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 55 | 0.540 |
Why?
| | Vomiting | 6 | 2019 | 131 | 0.540 |
Why?
| | Colorado | 15 | 2021 | 4588 | 0.540 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 194 | 0.540 |
Why?
| | Hypotension | 2 | 2022 | 125 | 0.530 |
Why?
| | Prospective Studies | 18 | 2023 | 8087 | 0.520 |
Why?
| | Drug Storage | 2 | 2017 | 52 | 0.520 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1098 | 0.510 |
Why?
| | Child | 28 | 2023 | 22638 | 0.510 |
Why?
| | Accidents, Home | 1 | 2017 | 32 | 0.510 |
Why?
| | Medical Marijuana | 2 | 2019 | 119 | 0.500 |
Why?
| | Cannabinoids | 3 | 2017 | 181 | 0.500 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 92 | 0.490 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.490 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 245 | 0.490 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.490 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 50 | 0.480 |
Why?
| | Electronic Health Records | 4 | 2024 | 1208 | 0.480 |
Why?
| | Hypocalcemia | 1 | 2016 | 40 | 0.470 |
Why?
| | Health Records, Personal | 1 | 2016 | 27 | 0.470 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 68 | 0.460 |
Why?
| | Blood Proteins | 1 | 2017 | 239 | 0.460 |
Why?
| | Mobile Applications | 1 | 2018 | 193 | 0.460 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.450 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 266 | 0.450 |
Why?
| | Antidepressive Agents | 2 | 2012 | 234 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1370 | 0.440 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 53 | 0.430 |
Why?
| | Liver | 6 | 2022 | 1859 | 0.430 |
Why?
| | Electrocardiography | 5 | 2013 | 666 | 0.420 |
Why?
| | Infant | 13 | 2023 | 10093 | 0.420 |
Why?
| | Treatment Outcome | 18 | 2020 | 11744 | 0.420 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 102 | 0.410 |
Why?
| | Child, Preschool | 13 | 2018 | 11888 | 0.400 |
Why?
| | Crime | 2 | 2011 | 58 | 0.400 |
Why?
| | Observer Variation | 3 | 2010 | 355 | 0.400 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.390 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 28 | 0.390 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 11 | 0.390 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.380 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 358 | 0.380 |
Why?
| | Diet Surveys | 1 | 2013 | 89 | 0.380 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.380 |
Why?
| | Accidents | 1 | 2013 | 43 | 0.380 |
Why?
| | Bradycardia | 1 | 2013 | 63 | 0.380 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.380 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.380 |
Why?
| | Adolescent | 27 | 2020 | 22451 | 0.380 |
Why?
| | Phytotherapy | 1 | 2013 | 74 | 0.380 |
Why?
| | Double-Blind Method | 7 | 2020 | 2064 | 0.370 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 86 | 0.370 |
Why?
| | Stomach Diseases | 1 | 2012 | 18 | 0.370 |
Why?
| | Foreign Bodies | 2 | 2011 | 109 | 0.370 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.370 |
Why?
| | beta-Alanine | 1 | 2012 | 25 | 0.370 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 49 | 0.370 |
Why?
| | Citalopram | 1 | 2012 | 33 | 0.360 |
Why?
| | Liver Function Tests | 7 | 2020 | 103 | 0.360 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 782 | 0.360 |
Why?
| | Antithrombins | 1 | 2012 | 70 | 0.360 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.350 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.350 |
Why?
| | Antifungal Agents | 1 | 2013 | 153 | 0.350 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.340 |
Why?
| | C-Peptide | 2 | 2010 | 191 | 0.340 |
Why?
| | Anaphylaxis | 2 | 2012 | 105 | 0.340 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2455 | 0.340 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 9 | 0.340 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.340 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 429 | 0.340 |
Why?
| | Dronabinol | 4 | 2021 | 250 | 0.340 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4565 | 0.340 |
Why?
| | Benzimidazoles | 1 | 2012 | 189 | 0.340 |
Why?
| | Temperance | 2 | 2010 | 20 | 0.340 |
Why?
| | Alcohol Drinking | 4 | 2012 | 847 | 0.330 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 727 | 0.330 |
Why?
| | Aged | 27 | 2019 | 26251 | 0.330 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.330 |
Why?
| | Administration, Intravenous | 4 | 2016 | 172 | 0.330 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.330 |
Why?
| | Brain Edema | 1 | 2011 | 63 | 0.330 |
Why?
| | Amitriptyline | 2 | 2001 | 25 | 0.330 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 611 | 0.320 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 109 | 0.320 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 128 | 0.320 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3396 | 0.320 |
Why?
| | Immunologic Factors | 2 | 2019 | 244 | 0.320 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 179 | 0.320 |
Why?
| | Liver Failure | 1 | 2011 | 75 | 0.320 |
Why?
| | Burns | 2 | 2015 | 365 | 0.310 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.310 |
Why?
| | Aged, 80 and over | 15 | 2018 | 8351 | 0.310 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.310 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.310 |
Why?
| | Population Surveillance | 1 | 2013 | 477 | 0.310 |
Why?
| | Barium | 1 | 2009 | 27 | 0.310 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.310 |
Why?
| | Time Factors | 12 | 2020 | 7079 | 0.300 |
Why?
| | Hypokalemia | 1 | 2009 | 23 | 0.300 |
Why?
| | Imines | 2 | 2022 | 6 | 0.300 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.300 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 97 | 0.300 |
Why?
| | United States | 18 | 2025 | 16041 | 0.300 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.300 |
Why?
| | Deception | 1 | 2009 | 17 | 0.300 |
Why?
| | Random Allocation | 3 | 2007 | 365 | 0.290 |
Why?
| | Warfarin | 1 | 2010 | 179 | 0.290 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 70 | 0.290 |
Why?
| | Benzoquinones | 2 | 2022 | 46 | 0.290 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 73 | 0.290 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5875 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6050 | 0.280 |
Why?
| | Odds Ratio | 7 | 2017 | 1070 | 0.280 |
Why?
| | Fluorides | 2 | 2016 | 50 | 0.280 |
Why?
| | Risk Assessment | 8 | 2017 | 3678 | 0.280 |
Why?
| | Risk Factors | 9 | 2017 | 10840 | 0.280 |
Why?
| | Oximetry | 1 | 2009 | 124 | 0.280 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 96 | 0.270 |
Why?
| | Length of Stay | 3 | 2020 | 1342 | 0.270 |
Why?
| | Eyelashes | 1 | 2008 | 3 | 0.270 |
Why?
| | Cyanoacrylates | 1 | 2008 | 3 | 0.270 |
Why?
| | Reference Values | 4 | 2017 | 787 | 0.270 |
Why?
| | Adhesives | 1 | 2008 | 15 | 0.270 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 185 | 0.270 |
Why?
| | Detergents | 1 | 2008 | 42 | 0.270 |
Why?
| | Intellectual Disability | 1 | 2009 | 178 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 115 | 0.260 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.260 |
Why?
| | Hypoglycemia | 2 | 2010 | 489 | 0.260 |
Why?
| | Alcoholism | 4 | 2023 | 830 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 649 | 0.260 |
Why?
| | Animals | 22 | 2019 | 38030 | 0.260 |
Why?
| | Diazepam | 1 | 2007 | 32 | 0.260 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 96 | 0.260 |
Why?
| | Niacin | 1 | 2007 | 16 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 384 | 0.250 |
Why?
| | Vitamin B Complex | 1 | 2007 | 39 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.240 |
Why?
| | Thromboembolism | 1 | 2007 | 129 | 0.240 |
Why?
| | Pediatrics | 1 | 2015 | 1122 | 0.240 |
Why?
| | Specimen Handling | 1 | 2008 | 178 | 0.240 |
Why?
| | Pyrazoles | 2 | 2023 | 516 | 0.230 |
Why?
| | Analgesics | 4 | 2017 | 231 | 0.230 |
Why?
| | Decontamination | 1 | 2006 | 28 | 0.230 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.230 |
Why?
| | Amiodarone | 1 | 2005 | 31 | 0.230 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 50 | 0.230 |
Why?
| | Self Report | 4 | 2021 | 869 | 0.230 |
Why?
| | Age Factors | 7 | 2017 | 3321 | 0.230 |
Why?
| | Eating | 4 | 2017 | 386 | 0.220 |
Why?
| | Intention | 1 | 2007 | 187 | 0.220 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 19 | 0.220 |
Why?
| | Venous Thrombosis | 1 | 2007 | 195 | 0.220 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.220 |
Why?
| | Anticoagulants | 1 | 2010 | 743 | 0.220 |
Why?
| | Drug Utilization | 5 | 2014 | 170 | 0.220 |
Why?
| | Calcium | 3 | 2016 | 1181 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 397 | 0.210 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 74 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1754 | 0.210 |
Why?
| | Education, Medical | 2 | 2021 | 273 | 0.210 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 340 | 0.210 |
Why?
| | Databases, Factual | 1 | 2010 | 1481 | 0.210 |
Why?
| | Coma | 2 | 2006 | 39 | 0.210 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 861 | 0.210 |
Why?
| | Biomarkers | 7 | 2021 | 4329 | 0.200 |
Why?
| | Hospitals, Urban | 5 | 2021 | 140 | 0.200 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 115 | 0.200 |
Why?
| | Triage | 2 | 2025 | 243 | 0.200 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 46 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 8 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3633 | 0.190 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1992 | 0.190 |
Why?
| | Calcium Chloride | 1 | 2003 | 10 | 0.190 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 211 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 119 | 0.190 |
Why?
| | Insulin | 3 | 2019 | 2524 | 0.190 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1411 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 302 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 190 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 92 | 0.180 |
Why?
| | Documentation | 1 | 2024 | 202 | 0.180 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 179 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2112 | 0.170 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 122 | 0.170 |
Why?
| | Confidence Intervals | 4 | 2010 | 328 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 184 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 334 | 0.170 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2910 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1139 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 119 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 24 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 139 | 0.160 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 209 | 0.160 |
Why?
| | Fractures, Bone | 2 | 2017 | 431 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 1033 | 0.160 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 195 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2001 | 292 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.150 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.150 |
Why?
| | Lithium Carbonate | 1 | 1999 | 4 | 0.150 |
Why?
| | Wisconsin | 1 | 2020 | 102 | 0.150 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 4 | 0.150 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.150 |
Why?
| | Starch | 1 | 2019 | 22 | 0.150 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.150 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.150 |
Why?
| | Survival Analysis | 4 | 2010 | 1372 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 41 | 0.150 |
Why?
| | Healthy Volunteers | 2 | 2019 | 217 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 205 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 37 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 24 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 181 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 238 | 0.140 |
Why?
| | Administration, Oral | 4 | 2019 | 867 | 0.140 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.140 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 6 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 145 | 0.140 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.140 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.140 |
Why?
| | Metabolome | 1 | 2022 | 390 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1034 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 191 | 0.140 |
Why?
| | Community Health Workers | 1 | 2020 | 89 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1300 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 511 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 6045 | 0.130 |
Why?
| | Sex Factors | 5 | 2022 | 2101 | 0.130 |
Why?
| | Sulfasalazine | 1 | 1998 | 22 | 0.130 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.130 |
Why?
| | Cannabidiol | 1 | 2020 | 142 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2020 | 251 | 0.130 |
Why?
| | Drug Interactions | 4 | 2014 | 403 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2021 | 305 | 0.130 |
Why?
| | Dietary Fats | 1 | 2019 | 307 | 0.130 |
Why?
| | Dyspnea | 1 | 1999 | 251 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 234 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 693 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 62 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 297 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1526 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 121 | 0.120 |
Why?
| | Incidence | 4 | 2013 | 2910 | 0.120 |
Why?
| | Survival Rate | 3 | 2013 | 2078 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 353 | 0.120 |
Why?
| | Ammonium Compounds | 1 | 2016 | 2 | 0.120 |
Why?
| | Mice | 8 | 2009 | 18266 | 0.120 |
Why?
| | Energy Intake | 1 | 2019 | 506 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 310 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 136 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 63 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 157 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1062 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 221 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 25 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 413 | 0.110 |
Why?
| | Milk | 1 | 2016 | 117 | 0.110 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2097 | 0.110 |
Why?
| | Genetic Variation | 1 | 2020 | 992 | 0.110 |
Why?
| | Herniorrhaphy | 1 | 2016 | 69 | 0.110 |
Why?
| | Fatal Outcome | 2 | 2013 | 302 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 234 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1758 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1878 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 58 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 18 | 0.100 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 33 | 0.100 |
Why?
| | Patient Simulation | 1 | 2014 | 42 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 100 | 0.100 |
Why?
| | Transaminases | 1 | 2014 | 22 | 0.100 |
Why?
| | Oxycodone | 1 | 2014 | 52 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 954 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | Food | 1 | 2015 | 149 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1074 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 55 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 183 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1269 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 58 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 86 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 67 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4331 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.090 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 10 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2019 | 605 | 0.090 |
Why?
| | Canada | 2 | 2025 | 430 | 0.090 |
Why?
| | Walking | 1 | 2017 | 544 | 0.090 |
Why?
| | Dabigatran | 1 | 2012 | 30 | 0.090 |
Why?
| | Pain Measurement | 4 | 2019 | 567 | 0.090 |
Why?
| | Tachycardia | 1 | 2012 | 58 | 0.090 |
Why?
| | Chlorides | 1 | 2013 | 138 | 0.090 |
Why?
| | Sleep Stages | 1 | 2012 | 76 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 215 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 647 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 86 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 97 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 28 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 155 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 93 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1212 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 78 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 58 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 991 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 399 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 248 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2013 | 201 | 0.080 |
Why?
| | Sulfides | 1 | 2012 | 92 | 0.080 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.080 |
Why?
| | Levamisole | 1 | 2011 | 22 | 0.080 |
Why?
| | Accidental Falls | 2 | 2011 | 226 | 0.080 |
Why?
| | Laparoscopy | 1 | 2016 | 474 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 24 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 561 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5397 | 0.080 |
Why?
| | Molecular Structure | 1 | 2012 | 483 | 0.080 |
Why?
| | Drug Contamination | 1 | 2011 | 56 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 586 | 0.080 |
Why?
| | Universities | 1 | 2013 | 450 | 0.080 |
Why?
| | Sports | 1 | 2013 | 216 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 176 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 5 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 16 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 30 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 964 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 290 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 146 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 243 | 0.070 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 22 | 0.070 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 15 | 0.070 |
Why?
| | Watchful Waiting | 1 | 2010 | 90 | 0.070 |
Why?
| | Aripiprazole | 1 | 2009 | 18 | 0.070 |
Why?
| | Risperidone | 1 | 2009 | 27 | 0.070 |
Why?
| | Role | 1 | 2009 | 28 | 0.070 |
Why?
| | Potassium | 1 | 2009 | 151 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 30 | 0.070 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 142 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 162 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 105 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 369 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 37 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 516 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 68 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 458 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 190 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 227 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 293 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 340 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 50 | 0.070 |
Why?
| | Workload | 1 | 2010 | 169 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 18 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 3 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 11 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 90 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 519 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 194 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 24 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 55 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 77 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 455 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 90 | 0.060 |
Why?
| | Students | 1 | 2013 | 647 | 0.060 |
Why?
| | Drug Synergism | 1 | 2008 | 353 | 0.060 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 14 | 0.060 |
Why?
| | Laboratories | 1 | 2008 | 109 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 334 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1101 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 175 | 0.060 |
Why?
| | Polypharmacy | 1 | 2008 | 94 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 110 | 0.060 |
Why?
| | Research | 2 | 2011 | 421 | 0.060 |
Why?
| | Formates | 1 | 2006 | 15 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 204 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 23 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 209 | 0.060 |
Why?
| | Military Personnel | 1 | 2014 | 715 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1269 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 43 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 702 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 423 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 51 | 0.060 |
Why?
| | Probability | 2 | 2010 | 308 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 50 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 73 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 330 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 21 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 142 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 160 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2468 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 176 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 51 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1983 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 86 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 45 | 0.050 |
Why?
| | Geriatrics | 1 | 2006 | 96 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1581 | 0.050 |
Why?
| | Telemedicine | 1 | 2014 | 956 | 0.050 |
Why?
| | Risk | 1 | 2007 | 917 | 0.050 |
Why?
| | Spine | 1 | 2006 | 184 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 711 | 0.050 |
Why?
| | Water | 1 | 2008 | 451 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 312 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 601 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 22 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 267 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2357 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 314 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 399 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 117 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 347 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 870 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 465 | 0.050 |
Why?
| | Urea | 1 | 2023 | 84 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 404 | 0.050 |
Why?
| | Internet | 1 | 2007 | 656 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 454 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7217 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 82 | 0.040 |
Why?
| | Sex Distribution | 2 | 2015 | 379 | 0.040 |
Why?
| | Culture Techniques | 1 | 2001 | 65 | 0.040 |
Why?
| | Urban Population | 2 | 2019 | 496 | 0.040 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 12 | 0.040 |
Why?
| | Prevalence | 3 | 2015 | 2852 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 92 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 560 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2411 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 26 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 47 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 56 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 633 | 0.040 |
Why?
| | Certification | 1 | 2020 | 117 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 57 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 824 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 14 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 83 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1293 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 114 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 36 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 37 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 135 | 0.030 |
Why?
| | North America | 1 | 1999 | 299 | 0.030 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 47 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 627 | 0.030 |
Why?
| | Laparotomy | 1 | 1998 | 109 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1361 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 180 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 339 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 99 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 899 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 527 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 612 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 278 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 715 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1323 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 281 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2382 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1075 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 112 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 29 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 57 | 0.030 |
Why?
| | Observation | 1 | 2014 | 51 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 108 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 945 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 142 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 377 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 106 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 99 | 0.020 |
Why?
| | Erythropoietin | 1 | 1994 | 100 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2013 | 34 | 0.020 |
Why?
| | Protein Binding | 1 | 2020 | 2239 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 256 | 0.020 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 82 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 145 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 68 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 384 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 69 | 0.020 |
Why?
| | Iron | 1 | 1994 | 359 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 67 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 61 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1014 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 23 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 558 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 163 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 124 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1247 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 152 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 108 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 692 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 420 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 246 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 197 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 129 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 769 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 611 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 395 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 351 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 582 | 0.020 |
Why?
| | Safety | 1 | 2010 | 346 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 994 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 629 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 462 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 535 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 649 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 101 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 29 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1866 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.010 |
Why?
| | Contraindications | 1 | 2006 | 88 | 0.010 |
Why?
| | Clinical Competence | 1 | 2014 | 1261 | 0.010 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 79 | 0.010 |
Why?
| | Amyloidosis | 1 | 2006 | 43 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2006 | 134 | 0.010 |
Why?
| | Metabolomics | 1 | 2012 | 737 | 0.010 |
Why?
| | European Union | 1 | 2005 | 13 | 0.010 |
Why?
| | Electric Countershock | 1 | 2006 | 126 | 0.010 |
Why?
| | Fever | 1 | 2007 | 320 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 173 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 109 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 567 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6449 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 207 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 172 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 840 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 172 | 0.010 |
Why?
| | Swine | 1 | 2006 | 821 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 103 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 499 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 67 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3186 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1041 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 194 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1761 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 21 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1114 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1824 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1843 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2533 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5574 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2944 | 0.000 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|